Agios/$AGIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
- Ticker
- $AGIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 540
- Headquarters
- Cambridge, United States
- Website
- www.agios.com
Agios Metrics
BasicAdvanced
$2.1B
-
-$7.01
0.60
-
Price and volume
Market cap
$2.1B
Beta
0.6
52-week high
$46.00
52-week low
$22.24
Average daily volume
1.1M
Financial strength
Current ratio
10.221
Quick ratio
9.14
Long term debt to equity
0.012
Total debt to equity
0.03
Profitability
EBITDA (TTM)
-453.671
Gross margin (TTM)
-270.79%
Net profit margin (TTM)
-418.24%
Operating margin (TTM)
-466.78%
Effective tax rate (TTM)
0.25%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-22.24%
Return on equity (TTM)
-34.34%
Valuation
Price to revenue (TTM)
20.83
Price to book
2.03
Price to tangible book (TTM)
2.03
Price to free cash flow (TTM)
-5.249
Free cash flow yield (TTM)
-19.05%
Free cash flow per share (TTM)
-6.649
Growth
Revenue change (TTM)
140.58%
Earnings per share change (TTM)
-162.99%
3-year revenue growth (CAGR)
69.63%
10-year revenue growth (CAGR)
7.01%
3-year earnings per share growth (CAGR)
22.53%
10-year earnings per share growth (CAGR)
5.15%
What the Analysts think about Agios
Analyst ratings (Buy, Hold, Sell) for Agios stock.
Analyst projections of the future price of Agios stock.
Bulls say / Bears say
Worldwide mitapivat revenue rose to $44.7 million in Q2 2026 from $12.5 million a year earlier, and 442 US prescriptions had been written for AQVESME by quarter-end. This gives Agios a growing commercial base in thalassaemia. (SEC)
Mitapivat has a near-term growth opportunity in sickle cell disease: the FDA granted priority review with a 1 November 2026 decision date, and RISE UP analyses found fewer patients required transfusions than on placebo. Approval could open a substantially larger use for the drug, although it is not assured. (Agios Pharmaceuticals, Agios Pharmaceuticals)
Agios had $964.8 million in cash, cash equivalents and marketable securities at the end of June 2026. The company said this, alongside expected revenue and interest income, should fund its commercial plans and pipeline work, limiting near-term financing pressure. (SEC)
Mitapivat’s Phase 3 sickle cell results were mixed: the annualised pain-crisis endpoint did not reach statistical significance, and there was no overall difference in the fatigue endpoint. That leaves uncertainty about the breadth of clinical benefit, even with positive transfusion analyses. (Agios Pharmaceuticals)
Agios stopped developing tebapivat in both lower-risk myelodysplastic syndromes and sickle cell disease after the trials failed to meet its advancement threshold or show a sufficiently differentiated profile. Losing these programmes narrows the pipeline and increases reliance on mitapivat. (Reuters)
The company remains loss-making: it reported a $199.8 million net loss in the first half of 2026, while cash and marketable securities fell from $1.2 billion at the end of 2025 to $964.8 million at June-end. Continued high spending could erode the financial cushion before the business reaches profitability. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Agios Financial Performance
Revenues and expenses
Agios Earnings Performance
Company profitability
Upcoming events
No upcoming events
Agios News
AllArticlesVideos
Funds containing Agios
AllUSDEURGBP
Fund name | Fund size | $AGIO weighting |
|---|---|---|
iShares Ageing Population£AGES | $953M | 0.16% |
iShares Ageing Population$AGED | $953M | 0.16% |
iShares Ageing Population€AGED | $903M | 0.16% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.